The invention relates to compounds of formula (I):
or a salt thereof, wherein R
1
, G, L
1
, L
2
, L
3
, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, αvβ
1
integrin and αvβ
6
integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
Intramolecular Oxidative Coupling between Unactivated Aliphatic C–H and Aryl C–H Bonds
作者:Yang Liao、Yi Zhou、Zhen Zhang、Junzhen Fan、Feng Liu、Zhangjie Shi
DOI:10.1021/acs.orglett.0c04239
日期:2021.2.19
Direct oxidative coupling of different inert C–Hbonds is the most straightforward and environmentally benign method to construct C–C bonds. In this paper, we developed a Pd-catalyzed intramolecularoxidative coupling between unactivated aliphatic and aryl C–Hbonds. This chemistry showed great potential to build up fused cyclic scaffolds from linear substrates through oxidative couplings. Privileged
Birch reductio and reductivemethylations of some substituted naphtholic acids have been examined. The factors influencing the mechanism of reduction process have been discussed. Some of the reduced naphthoic acids are useful synthons for synthesis.
[EN] RAPID CONSTRUCTION OF TETRALIN, CHROMANE, AND INDANE MOTIFS VIA CYCLATIVE C-H/C-H COUPLING<br/>[FR] CONSTRUCTION RAPIDE DE MOTIFS DE TÉTRALINE, DE CHROMANE ET D'INDANE PAR COUPLAGE C-H/C-H PAR CYCLISATION
申请人:SCRIPPS RESEARCH INST
公开号:WO2022103752A1
公开(公告)日:2022-05-19
Disclosed herein is a process for achieving a palladium-catalyzed cyclative C(sp3)-H/C(sp2)-H coupling reaction using a native free carboxylic acid as a directing group, an amino acid ligand, and oxidant. The process is useful for synthesizing a range of biologically important scaffolds, including tetralins, chromanes, and indanes.
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.